ChiCTR2000041588 版本V1.4 版本创建时间2021/03/19 11:57:49 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2000041588 

最近更新日期:

Date of Last Refreshed on:

2021-03-15 17:19:11 

注册时间:

Date of Registration:

2020-12-31 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

【辑】组织纤溶酶原激活剂治疗视网膜下出血的临床研究

Public title:

Clinical study of tissue plasminogen activator in the treatment of subretinal hemorrhage

注册题目简写:

English Acronym:

研究课题的正式科学名称:

眼部应用组织纤溶酶原激活剂治疗视网膜下出血的临床研究

Scientific title:

Clinical study of tissue plasminogen activator in the treatment of subretinal hemorrhage

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

秦雪娇 

研究负责人:

秦雪娇 

Applicant:

Xuejiao Qin 

Study leader:

Xuejiao Qin 

申请注册联系人电话:

Applicant telephone:

+86 18560087100

研究负责人电话:

Study leader's telephone:

+86 18560087100

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

qinxuejiao@hotmail.com

研究负责人电子邮件:

Study leader's E-mail:

qinxuejiao@hotmail.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

山东省济南市文化西路107号

研究负责人通讯地址:

山东省济南市文化西路107号

Applicant address:

107 Wenhuaxi Road West, Ji'nan, Shandong, China

Study leader's address:

107 Wenhuaxi Road West, Ji'nan, Shandong, China+++++++

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

山东大学齐鲁医院

Applicant's institution:

Qilu Hospital of Shandong University

研究负责人所在单位:

山东大学齐鲁医院

Affiliation of the Leader:

Qilu Hospital of Shandong University

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

KYLL-202008-083

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

山东大学齐鲁医院医学伦理委员会

Name of the ethic committee:

Medical ethic committee of Qilu hospital of Shandong University

伦理委员会批准日期:

Date of approved by ethic committee:

2020-09-25 00:00:00

伦理委员会联系人:

卜丽娟

Contact Name of the ethic committee:

Lijuan Bu

伦理委员会联系地址:

济南市文化西路107号山东大学齐鲁医院科研处

Contact Address of the ethic committee:

Research Department of Qilu Hospital, Shandong University, 107 Wenhuaxi Road West, Ji'nan, Shandong, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

山东大学齐鲁医院

Primary sponsor:

Qilu Hospital of Shandong University

研究实施负责(组长)单位地址:

山东省济南市文化西路107号

Primary sponsor's address:

107 Wenhuaxi Road West, Ji'nan, Shandong, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

山东

市(区县):

济南

Country:

China

Province:

Shandong

City:

Ji'nan

单位(医院):

山东大学齐鲁医院

具体地址:

文化西路107号

Institution
hospital:

Qilu Hospital of Shandong University

Address:

107 Wenhuaxi Road West

经费或物资来源:

部分由医院资助

Source(s) of funding:

Partially from the hospital

Target disease:

Subretinal hemorrhage

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

非随机对照试验 

Study design:

Non randomized control 

研究目的:

探索一种安全、有效、方便的治疗视网膜下出血的方法。  

Objectives of Study:

To find a safe, effective and convenient method to treat subretinal hemorrhage.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

累及黄斑区的视网膜下出血患者。

Inclusion criteria

Patients with subretinal hemorrhage involving the macular region.

排除标准:

严重全身性疾病患者,
服用抗凝药物的患者,
不能随访的患者

Exclusion criteria:

1. Patients with severe systemic diseases,
2. Patients taking anticoagulants,
3. Patients who cannot be followed up.

研究实施时间:

Study execute time:

From 2021-01-01 00:00:00 To 2022-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-01-01 00:00:00 To 2022-07-03 00:00:00  

干预措施:

Interventions:

组别:

治疗组

样本量:

30

Group:

Treatment

Sample size:

干预措施:

tPA+anti-VEGF

干预措施代码:

Intervention:

tPA+anti-VEGF

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

山东 

市(区县):

济南 

Country:

China 

Province:

Shandong 

City:

Ji'nan 

单位(医院):

山东大学齐鲁医院 

单位级别:

三甲 

Institution
hospital:

Qilu Hospital of Shandong University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

出血量

指标类型:

主要指标

Outcome:

Hemorrhage

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

视功能

指标类型:

主要指标

Outcome:

visual acuity

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

视力

指标类型:

主要指标

Outcome:

visualacuity

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

出血量

指标类型:

主要指标

Outcome:

hemorrghage

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

病程

指标类型:

次要指标

Outcome:

duration

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

N/A

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 14 years
最大 Max age 100 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

非随机研究

Randomization Procedure (please state who generates the random number sequence and by what method):

Non-random

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

论文展示

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Publications

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2020-12-31 23:56:50